Immunic Q3 EPS Boosted by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS estimate to a loss of $0.84 per share from $1.07, and forecasts a $3.86-per-share loss for full-year 2026.
• Immunic reported a Q2 loss of $0.80 per share, beating the $1.16 consensus estimate by $0.36 per share.
• Analyst sentiment remains broadly positive, with a consensus Buy rating and a $47.57 price target, although the company remains unprofitable and its outlook depends on advancing its clinical-stage drug pipeline.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at Brookline Capital Markets lifted their Q3 2026 earnings per share estimates for shares of Immunic in a research note issued on Wednesday, August 12th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will post earnings of ($0.84) per share for the quarter, up from their previous estimate of ($1.07). The consensus estimate for Immunic's current full-year earnings is ($3.93) per share. Brookline Capital Markets also issued estimates for Immunic's Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($3.86) EPS.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36.

IMUX has been the subject of several other research reports. Roth Capital restated a "buy" rating and set a $19.00 price target on shares of Immunic in a report on Thursday, May 14th. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective (up from $5.00) on shares of Immunic in a research report on Thursday, April 30th. LADENBURG THALM/SH SH raised shares of Immunic to a "strong-buy" rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of Immunic from a "sell" rating to a "hold" rating in a report on Saturday. Finally, B. Riley Financial cut their price target on shares of Immunic from $40.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 22nd. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $47.57.

Immunic Price Performance

Immunic stock opened at $16.06 on Monday. The stock's 50 day moving average is $14.45 and its 200 day moving average is $12.10. Immunic has a one year low of $5.06 and a one year high of $16.86. The firm has a market cap of $219.06 million, a P/E ratio of -3.67 and a beta of 1.41.

Institutional Trading of Immunic

Large investors have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp acquired a new stake in Immunic in the first quarter worth $187,000. Avidity Partners Management LP raised its holdings in shares of Immunic by 42.6% during the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock valued at $7,436,000 after purchasing an additional 2,000,000 shares during the period. Renaissance Technologies LLC bought a new position in shares of Immunic during the 1st quarter worth about $1,020,000. XTX Topco Ltd acquired a new stake in shares of Immunic in the 4th quarter valued at about $120,000. Finally, Jane Street Group LLC grew its stake in shares of Immunic by 46.8% in the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company's stock valued at $153,000 after buying an additional 91,346 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

Key Headlines Impacting Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright significantly improved its earnings forecasts across 2026–2030. The firm now projects smaller losses of $3.18 per share in 2026, $2.47 in 2027, $1.45 in 2028 and $0.53 in 2029, followed by positive EPS of $0.40 in 2030. HC Wainwright maintained a Buy rating and a $22 price target, suggesting potential upside from current levels.
• Positive Sentiment: HC Wainwright also raised its third- and fourth-quarter 2026 EPS estimates to losses of $0.74 and $0.68, respectively, from substantially larger projected losses. This indicates expectations for improved operating performance and a faster path toward profitability.
• Positive Sentiment: Brookline Capital Markets raised its full-year 2026 EPS forecast to a $3.86 loss from a $4.34 loss and improved its third-quarter estimate to a $0.84 loss from $1.07, reinforcing the view that Immunic’s near-term losses could narrow.
• Neutral Sentiment: Wall Street Zen upgraded its assessment of Immunic to Hold. The rating is less bullish than HC Wainwright’s view and could limit enthusiasm among investors seeking a stronger consensus signal. Immunic Raised to Hold at Wall Street Zen
• Negative Sentiment: Brookline slightly reduced its fourth-quarter 2026 estimate to a $1.16-per-share loss from $1.14. More broadly, Immunic remains unprofitable, with the analyst consensus calling for a $4.49-per-share loss in the current year. The company’s valuation therefore remains highly dependent on successful development and eventual commercialization of its pipeline.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source